Eton Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5
- Today's High:
- $5.4499
- Open Price:
- $5.2
- 52W Low:
- $1.95
- 52W High:
- $4.28
- Prev. Close:
- $5.19
- Volume:
- 469751
Company Statistics
- Market Cap.:
- $97.43 million
- Book Value:
- 0.441
- Revenue TTM:
- $24.38 million
- Operating Margin TTM:
- -23.41%
- Gross Profit TTM:
- $14.32 million
- Profit Margin:
- -26.05%
- Return on Assets TTM:
- -15.14%
- Return on Equity TTM:
- -51.58%
Company Profile
Eton Pharmaceuticals Inc had its IPO on 2018-11-13 under the ticker symbol ETON.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Eton Pharmaceuticals Inc has a staff strength of 28 employees.
Stock update
Shares of Eton Pharmaceuticals Inc opened at $5.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5 - $5.45, and closed at $5.27.
This is a +1.54% increase from the previous day's closing price.
A total volume of 469,751 shares were traded at the close of the day’s session.
In the last one week, shares of Eton Pharmaceuticals Inc have increased by +15.32%.
Eton Pharmaceuticals Inc's Key Ratios
Eton Pharmaceuticals Inc has a market cap of $97.43 million, indicating a price to book ratio of 7.0138 and a price to sales ratio of 4.3625.
In the last 12-months Eton Pharmaceuticals Inc’s revenue was $24.38 million with a gross profit of $14.32 million and an EBITDA of $-3982000. The EBITDA ratio measures Eton Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eton Pharmaceuticals Inc’s operating margin was -23.41% while its return on assets stood at -15.14% with a return of equity of -51.58%.
In Q1, Eton Pharmaceuticals Inc’s quarterly earnings growth was a negative -12.6% while revenue growth was a positive 143.8%.
Eton Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 312.5
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.25 per share while it has a forward price to earnings multiple of 312.5 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eton Pharmaceuticals Inc’s profitability.
Eton Pharmaceuticals Inc stock is trading at a EV to sales ratio of 3.7901 and a EV to EBITDA ratio of -10.3595. Its price to sales ratio in the trailing 12-months stood at 4.3625.
Eton Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $23.93 million
- Total Liabilities
- $7.49 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Eton Pharmaceuticals Inc ended 2024 with $23.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.93 million while shareholder equity stood at $11.24 million.
Eton Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $7.49 million in other current liabilities, 26000.00 in common stock, $-105794000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.71 million and cash and short-term investments were $14.71 million. The company’s total short-term debt was $1,339,000 while long-term debt stood at $5.11 million.
Eton Pharmaceuticals Inc’s total current assets stands at $19.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.87 million compared to accounts payable of $1.23 million and inventory worth $437000.00.
In 2024, Eton Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Eton Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.27
- 52-Week High
- $4.28
- 52-Week Low
- $1.95
- Analyst Target Price
- $10
Eton Pharmaceuticals Inc stock is currently trading at $5.27 per share. It touched a 52-week high of $4.28 and a 52-week low of $4.28. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $3.64 and 200-day moving average was $3.57 The short ratio stood at 14.24 indicating a short percent outstanding of 0%.
Around 1319.5% of the company’s stock are held by insiders while 2340.7% are held by institutions.
Frequently Asked Questions About Eton Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.